The 2020 meeting will again include representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies and industry to discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Steering Committee chaired by Drs. Susan Kornstein and Mark Rapaport with representation of the sectors that are part of the ASCP community lead the direction of the meeting. Representatives from the FDA, EMA, NIMH, NIDA, NIAAA, and academia comprise the 2019 Steering Committee. A Program Committee under the leadership of Drs. Erika Saunders and Lee Cohen are responsible for review of all program submissions.
ASCP Mission Statement
The mission of the American Society of Clinical Psychopharmacology is to advance the science and practice of clinical psychopharmacology.
ASCP Diversity Statement
The organization has a commitment to actively promote and welcome diversity and inclusion within the society and within our field. Diversity includes but is not limited to race, ethnicity, religion, disability, age, sex, gender identity, sexual orientation, intellectual perspectives and points of view.
ASCP Underrepresented in Biomedical Sciences Statement
ASCP URB (Underrepresented in Biomedical Sciences): Groups underrepresented within biomedical sciences are currently defined as African American, Hispanic, Native American, Pacific Islander, or Scientist with a Disability.
2019 ASCP Annual Meeting Submission Deadlines: